2009
- Received clearance to proceed to Phase 2b trial of inhaled formoterol HFA-MDI (PT005) following submission of a U.S. Investigational New Drug (IND) application
- Completed Phase 2a dose-ranging study to evaluate the safety and efficacy of inhaled glycopyrrolate HFA-MDI (PT001) in patients with chronic obstructive pulmonary disease (COPD)
- Completed Phase 1 healthy volunteer safety and pharmacokinetics study with glycopyrrolate-formoterol combination HFA-MDI (PT003)
- Completed Phase 2b enabling 14-day inhalation toxicology studies for formoterol HFA-MDI (PT005) and glycopyrrolate-formoterol combination HFA-MDI (PT003)
- Completed Phase 2a dose-ranging study to evaluate the safety and efficacy of inhaled formoterol HFA-MDI (PT005) in patients with COPD
- Filed patent application for new formulation platform
- Received clearance to proceed to Phase 2a trial of glycopyrrolate HFA-MDI (PT001) in COPD following submission of U.S. IND application
- Secured $8 million venture debt financing from Silicon Valley Bank and Oxford Finance
- Appointed Perry Karsen as Chief Executive Officer
2008
- Completed Phase 2b enabling 14-day inhalation tox study for glycopyrrolate HFA-MDI (PT001)
- Initiated Phase 2a dose-ranging study to evaluate the safety and efficacy of inhaled formoterol HFA-MDI (PT005) in patients with COPD
- Raised $18 million Series B2 financing to accelerate pipeline
- Established manufacturing pilot plant for clinical production
2007
- Initiated preclinical product development
- Appointed Michael Golden as Vice President, Regulatory Affairs and Quality
- Appointed Colin Reisner, M.D., as Chief Medical Officer
- Transferred technology from Nektar
- Established operations in California, North Carolina and New Jersey
- Raised $15.5 million Series B1 financing
- Obtained license to a fully developed pulmonary drug delivery platform from Nektar in exchange for Series A equity
2006
- Pearl founded by Sarvajna Dwivedi, Ph.D., and Adrian Smith, industry veterans with experience in drug development, specifically novel pulmonary therapeutics, with a vision of developing unique respiratory therapeutics utilizing a proprietary drug delivery platform and existing therapeutic agents administered in metered-dose inhalers